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Introduction
Major depressive disorder (MDD) is an
affective mood disorder with symptoms
characterized by persistent and pervasive
sadness, as well as low self-esteem and a loss of
interest or pleasure in activities (Maughan,
Collishaw, & Stringaris, 2013). Due to the
negative symptoms MDD produces, individuals
suffering from this disease may encounter a
reduction in marital functioning, timing and
stability, parental functioning, education,
employment status, and financial success
(Kessler, 2012). Also, MDD is commonly
associated with many chronic physical disorders,
such as arthritis, asthma, cancer, cardiovascular
disease, diabetes, hypertension, as well as chronic
respiratory disorders and pain conditions
(Kessler, 2012).
Out of all mental disorders MDD is the
fourth leading cause for disability worldwide and
is projected to be the second leading cause by
2020 (Kessler, 2012). Depression is a commonly
occurring disorder with lifetime prevalence rates
ranging from 1.5-19% (Kessler, 2012). Many
individuals that seek treatment for MDD often
find the ailment to be chronically reoccurring
(Kessler, 2012). Within a year there is a one third
to one half rate of reoccurrence for depressive
episodes in lifetime cases (Kessler, 2012).
The onset of many psychological
disorders can appear at any time across ones
lifespan (Wittchen, Nelson, & Lachner, 1998).
As for MDD, its development can be seen more
commonly in childhood and adolescence with a
prevalence rate of 4-8% for adolescents and 2%
in childhood (Hazell, 2009; Wittchen et al., 1998;
Kessler, Avenevoli, & Merikangas, 2001; Nardi,
Francesconi, Catena-Dell’osso, & Bellantuono,
2013). Many children and adolescents suffering
from depression tend to have a stronger
propensity for social withdrawal, substance
abuse, and other mental disorders, as well as a
decrease in school performance and social skills
(Kessler et al., 2001; Nardi, Francesconi, CatenaDell’osso, & Bellantuono, 2013). Within the
pediatric population, there is a 40-90% rate of comorbidity with other conditions such as,
dysthymia, autism spectrum disorders, ADHD,
and substance abuse (Vogel, 2012). Another
complication that is of major concern is the

increased risk of suicide within childhood and
adolescent populations due to the effects of major
depression (Vogel, 2012).
Within this young and vulnerable
population, it is possible that the diagnosis of
childhood and adolescent depression may often
remain unidentified, as a given depressive
episode may not reach the diagnostic threshold
for MDD (Nardi, Francesconi, Catena-Dell’osso,
& Bellantuono, 2013). The symptoms that linger
from an undiagnosed case of MDD can
potentially contain chronic clinical and social
implications, as well as lead to a fully developed
case of MDD for the depressed child (Nardi,
Francesconi, Catena-Dell’osso, & Bellantuono,
2013). Clinical features of MDD symptoms in
children and adolescents do not correlate directly
with the symptoms exhibited by adult populations
(Nardi, Francesconi, Catena-Dell’osso, &
Bellantuono, 2013).
Symptoms in adolescent
populations are duly expressed through somatic
complaints, including irritability, loss of energy
or fatigue, abdominal pain, and headaches (Nardi,
Francesconi, Catena-Dell’osso, & Bellantuono,
2013).
In regards to treatment of MDD, there is
a wide range of antidepressants that are
efficacious for use in adult populations (Ryan,
2005).
The first forms of psycho
pharmacotherapy for depression were discovered
in the 1960’s and are characterized as first
generation antidepressants, known as monoamine
oxidase inhibitors (MAOIs) and tricyclic
antidepressants (TCAs) (Olver, Burrows, &
Norman, 2001; Slattery, Hudson, & Nutt, 2004).
Due to these compounds broad method of action
by nonspecifically increasing monoamine levels
in the synapse through reuptake inhibition or
reduced metabolism, consequential side effects
are expressed (Olver, Burrows, & Norman,
2001). As a result of these adverse side effects
patient compliance with MAOIs and TCAs are
generally
low
(Montgomery,
2006).
Subsequently, a second generation of
antidepressants known as selective serotonin
reuptake inhibitors (SSRIs) was developed to
improve on method of action and safety (Olver,
Burrows, & Norman, 2001).
As for childhood and adolescent
populations, the options for treatment of MDD
are far less (Gordon & Melvin, 2013; Ryan,
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2005). Specifically, in 2003 the FDA issued the
SSRI fluoxetine as the only antidepressant that
could safely be used within the pediatric
population (Gordon et al., 2013; Masi, Liboni, &
Brovedani, 2010).
Compared to adults,
adolescents have different pharmacodynamics
and pharmacokinetics (Gordon et al., 2013).
Consequently, it appears that there is some
evidence for age-dependent effects of SSRIs in
humans and rodents (Olivier, Blom, Arentsen, &
Homberg, 2011).
Within the US the rate of suicide for
adolescents is approximately seven for every
100,000 individuals and most of those whom
committed suicide were suffering from a mental
disorder and half from MDD (Ryan, 2005).
Attempted suicide rates for adolescents suffering
from MDD are between 20-24% and rates of
suicidal ideation are 15-66%.
Given the
introduction
of
psychopharmaceutical
interventions for MDD in the form of
antidepressants, there appears to be a
correlational decrease in rates of suicide for
adolescents (Vogel, 2012).
Despite this
correlation there has been an increase in suicidal
ideation and attempts among adolescents who are
taking these antidepressants (Vogel, 2012). The
risk ratio for suicide attempts and suicidal
behavior or ideation as defined by the FDA for
fluoxetine is 0-92 and for paroxetine 2-65 (Ryan,
2005).
In
regards
to
paroxetine,
recommendations for prescribing the drug to
depressed pediatric populations has been greatly
cautioned due to paroxetine’s tendencies to
increase the risk of deliberate self-harm or
suicidal ideation (Soomro, 2008; Karanges et al.,
2011). Fluoxetine on the other hand, has received
adequate acceptance for treatment of MDD in the
use of pediatric populations (Hazell, 2009;
Gordon et al., 2013)
The clinical efficacy of fluoxetine and
paroxetines use in childhood and adolescence
remains to be certain due to differences observed
in associated risk of suicidal ideation or behavior
and potential benefits from the SSRIs (Soomro,
2008; Masi et al., 2010; Karanges et al., 2011).
Perplexingly, these SSRIs are similar in both
composition and method of action that is by
blocking the serotonin transporter in the
presynapse and thus increasing the amount of
serotonin in the presynaptic membrane

(Fitzgerald & Bronstein, 2013). Consequently,
the aim of the present research study is to further
extend the knowledge on the age-dependent
effects of chronic fluoxetine and paroxetine
treatment in adolescent male and female rats,
specifically in regards to anxiety and depression.
Furthermore, we aspire to measure
depression through the use of sucrose preference
for anhedonia, meaning the inability to draw
pleasure from previously joyful experiences.
Also, in regards to measuring anxiety we will be
using acoustic startle reflex, light/dark box, and
elevated plus maze. The aforementioned tests are
valid measures of depression due to their
manipulations that simulate states of depression
through maternal separation, chronic mild stress
or chronic dexamethasone treatment, dull sucrose
preference, a reduction of time spent in the open
arms of elevated plus maze, a reduction of time
spent in the lit arena of the light/dark box, and a
increase of prepulse inhibition and habituation in
the acoustic startle response (Hill, Hellemans,
Verma, Gorzalka, & Weinberg, 2012; Leussis,
Freund, Brenhouse, Thompson, & Andersen,
2012; Casarotto & Andreatini, 2007; Drapier et
al., 2007; Quednow et al., 2006; Tsoory, Cohen,
& Richter-Levin, 2007; Yacoubi, Rappeneau,
Champion,
Malleret,
Vaugeois,
2006).
Antidepressant treatment subsequently serves as
a method to improve scores on these tests
(Casarotto & Andreatini, 2007; Huot,
Thrivikraman, Meaney, & Plotsky, 2001; Wang,
Jiao, & Dulawa, 2011; Quednow et al., 2004).
Due to the present lack of definitive evidence in
the efficacy on the use of SSRIs in children under
the age of 13 (Vogel, 2012), we aim to examine
the SSRIs effects in this vulnerable population
with rats starting on postnatal day (PD) 30. As a
result of the prevalence rates of adolescent MDD
being twice as high for female humans than
males, we chose to investigate the effects of these
SSRIs on both sexes (Vogel, 2012; Frackiewicz,
Sarmek, & Cutler, 2000; Scheibe, Preuschhof,
Cristi, & Bagby, 2003).
Materials and Methods
Subjects
A total of ___ male and female rats of SpragueDawley descent (Charles River Laboratories,
Wilmington, MA), born and raised at California
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State University, San Bernardino (CSUSB) were
used. Litters were culled on PD 3 to a maximum
of 10 rat pups. Pups were housed with the dam
until PD 20. After weaning, rats were housed in
group cages with same-sex litter mates (4-6 rats
per cage). After the sucrose preference test (PD
60), rats were single housed for the remainder of
the behavioral experiments. A temperature of 2224°C and a 12-hr light/dark cycle was held inside
the colony room. All animals were treated
according to the “Guide for the Care and Use of
Mammals in Neuroscience and Behavioral
Research” (National research Council, 2010)
under a research protocol approved by the
Institutional Animal Care and Use Committee
and CSUSB.
Drugs
Fluoxetine hydrochloride and paroxetine
hydrochloride was obtained from Toronto
Research Chemicals (Toronto, Canada). Both
fluoxetine and paroxetine was dissolved in a 50%
dimethyl sulfoxide (DMSO)/water solution and
injected intraperitoneally (IP) at a volume of _
ml/kg.
Apparatus
EPM
The EPM was constructed out of black plastic and
was stationed 50 cm above floor level (San Diego
Instruments, San Diego). The EPM contained
four perpendicularly aligned arms, each of which
was 50 cm long and 10 cm wide. The two
enclosed arms contained 30 cm high walls, while
the two open arms were exposed with a .9 cm lip
for the prevention of rats falling of the EPM. The
EPM was stationed in the center of a quiet, dimly
lit room, with a digital video camera located
directly above the maze.
Acoustic startle response
The acoustic startle reflex will be measured with
the Coulbourn Animal Acoustic Startle System
(Coulbourn Instruments, Whitehall, PA), which
contains weight sensitive platforms inside
individual
sound-attenuating
chambers.
Ventilation fans built into the chambers produced
the background noise. Rats were placed in a
small, ventilated holding cage, which restricted
extensive locomotion.

Light-dark box
The light-dark box contained a 41 x 41 cm base
with
photobeam
receptors
(Coulbourn
Instruments, Whitehall, PA). The walls of the
chambers were 41 cm high.
The dark
compartment was composed of a dark plastic box
covering half of the base. The plastic box also
had a small transition door between the light and
dark compartments.
Procedures
Sucrose preference
Rats (N=10-11) began sucrose preference
training on PD 26 with a two-bottle choice test.
On day one of training, rats were individually
housed and habituated to drinking water from two
bottles. For the next three days (PD 27-30), one
of the two bottles contained either a .5 or 2%
sucrose solution. On each of the three days, the
bottles were weighed and refilled at the same time
every morning. To avoid position preferences,
the bottles were systematically switched to either
the left or right each day. On the last day of
sucrose training, (PD 29) rats were group housed
with same-sex littermates. On the following day,
rats were treated with paroxetine (2.5 or 10
mg/kg), fluoxetine (10 mg/kg), or vehicle once
daily from PD 30 to PD 59. Following the last
injection, rats were individually housed and given
a final sucrose preference test beginning on PD
59 and ending on PD 60. Sucrose preference was
defined using the following formula: [(weight of
sucrose ingested) / (weight of water ingested +
weight of sucrose ingested) x 100]. Assessment
of change in sucrose preference due to SSRI
treatment was accomplished by calculating
difference scores (i.e., the average of the three
baseline scores minus the final difference score).
Elevated plus maze
After the cessation of the sucrose preference test
on PD 60, rats designated for EPM testing were
individually brought to another quite testing
room. Each rat was placed in the middle of the
EPM with the head facing the open arm. Rats
were allowed to roam freely on the EPM for
approximately 5-min. Recordings of the rat’s
activity on the EPM (time spent in the center and
open or closed arms) was documented via a video
camera and scored afterwards. Data entries for
the open or closed arms were documented when
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all four paws crossed the thresholds. Data entry
for the center of the EPM was documented when
two paws crossed the threshold.
Light-dark box
Following the cessation of the sucrose preference
test on PD 60, rats designated for light-dark box
testing were brought (two at a time) to a quite
separate testing room. Each rat was individually
placed into the front right corner of the light-dark
box and given 10-min to roam freely. Data was
recorded for time spent in each of the light and
dark compartments, as well as the frequency of
transitions into the light compartment, and beam
interruptions in the light and dark compartments.
Acoustic startle reflex/prepulse inhibition
After the cessation of the sucrose preference test
on PD 60, rats designated for acoustic startle
reflex/prepulse inhibition were brought (two at a
time) to a quite separate testing room and were
placed into a testing chamber for a 5-min
acclimation period prior to the delivery of any
stimulus. Each session was conducted using a 70
dB white background noise. On the first and last
six trails of the session, a startling stimulus (50
dB above the background (or 120 dB), 40 ms)
was presented alone. The remaining trails were
presented in a pseudorandom order and included
12 trails (middle trails) with the startling stimulus
alone (used to calculate % PPI and average startle
amplitude), and 12 trails/prepulse stimulus
intensity on which a prepulse stimulus (20 ms)
preceded the startling stimulus by 100 ms. The
prepulse stimuli were 3, 6, 12, 15, or 18 dB above
the background. Additionally, there were 8 trails
on which no stimulus was presented, but activity
within the chamber was monitored. The intertrail inter will be 20 s. Startle amplitude on the
12 middle trails during which the startle stimulus
alone was presented was averaged. These data
were used in the analyses of baseline startle
amplitude. Percent prepulse inhibition was
calculated as [100 x (average startle amplitude on
the prepulse trails/average startle amplitude on
the middle startle stimulus alone trials)]. Percent
habituation will be calculated as [100 x average
startle amplitude on the last 6 startle alone
trails/average startle amplitude on the first 6
startle alone trails)].

Expected Results
In regards to body weight, we expect that
adolescent rats treated with fluoxetine and
paroxetine to have less weight gain than rats
treated with vehicle (Homberg et al., 2011;
Iñiguez, Warren, & Bolaños-Guzmán, 2010; de
Jong et al.,). Specifically, we plan to analyze data
from body weights obtained during injections
with a 3 x 2 x 30 (pretreatment condition x sex x
day) repeated measures ANOVA. Measurement
of anhedonia will be achieved through the use of
sucrose preference test, in which we expect
adolescent rats treated with fluoxetine and
paroxetine to show less sucrose consumption and
preference than rats treated with vehicle (Iñiguez,
Warren,
&
Bolaños-Guzmán,
2010).
Furthermore, we plan to analyze data from the
sucrose preference test with a 3 x 2 x 2
(pretreatment x sex x sucrose solution) repeated
measures ANOVA. For measurement of anxietylike behaviors we will be using the elevated plus
maze (EPM), in which we expect adolescent rats
treated with fluoxetine and paroxetine to spend
less time in the open arms of the EPM than rats
treated with vehicle (Homberg et al., 2011;
Vorhees, Morford, Graham, Skelton, & Williams,
2011; Oh, Zupan, Gross, & Toth, 2009; Iñiguez,
Warren, & Bolaños-Guzmán, 2010; Drapier et
al., 2007; de Jong et al., 2006). Moreover, we
plan to analyze data from the EPM with a 3 x 2
(pretreatment x sex) ANOVA. As for acoustic
startle response, we expect adolescent rats treated
with fluoxetine and paroxetine to exhibit a
consistent startle response where rats treated with
vehicle would show a decrease in startle response
(Homberg et al., 2011; Vorhees; de Jong et al.,
2006). In regards to the light/dark box, we expect
adolescent rats treated with fluoxetine and
paroxetine to stay in the dark compartment for a
longer period of time and take longer to emerge
into the light compartment when compared to rats
treated with vehicle (Arrant, Coburn, Jacobsen, &
Kuhn, 2013). Additionally, we plan to analyze
data from the light/dark box with a 3 x 2
(pretreatment x sex) ANOVA.
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